4 JUN 1981

NOT FOR PUBLICATION

ADVISORY COMMITTEE ON THE NATIONAL BLOOD TRANSFUSION SERVICE

The third meeting will take place on 22 June 1981 at 2 p.m. in room 32 Hannibal House, Elephant and Castle, London SE1

AGENDA

1. Apologies for absence and introductions.

2. Minutes of the last meeting - AC(81)9 - already circulated.

3. Matters arising:

   (a) Meeting with Directors of Haemophilia Centres - oral report by Dr Tovey and Dr Walford.

   (b) Supply of blood products to Northern Ireland - AC(81)10 attached (for information).

4. Working Party on plasma supply - AC(81)11 to follow.

5. Lorne Laboratories - possible collaborative venture with the NBTS - AC(81)12 attached.

6. Hepatitis vaccine - collaboration between the NBTS and a British pharmaceutical company - AC(81)13 to follow.

7. Any other business

8. Date of next meeting.

DHSS June 1981

1317

44/268

NOT FOR PUBLICATION

AC(81)10

ADVISORY COMMITTEE ON THE NBTS

FOR INFORMATION

SUPPLY OF BLOOD PRODUCTS TO NORTHERN IRELAND

1. At the meeting on 23 February it was reported that exploratory discussions were taking place between the Directors involved which may lead to the Northern Ireland Blood Transfusion Service sending plasma (both time-expired and fresh frozen) to the Protein Fractionation Centre, Edinburgh, instead of the Blood Products Laboratory.

2. A number of practical and technical problems remain to be resolved, and the Scottish Home and Health Department and the Department of Health and Social Services for Northern Ireland have to consider the implications of any such proposal as well as agreeing the financial terms on which such a scheme would be undertaken. The Advisory Committee will be kept informed of progress.

3. In the meantime, the Blood Products Laboratory will continue to fractionate plasma from Northern Ireland and the system of pro rata distribution of certain products (AC(81)3) will be applied in the same way as to other Transfusion Centres served by BPL.

44/269

5. It is likely that one Regional Transfusion Centre could meet Lorne's requirements without difficulty. For the purpose of a. above, fully characterised (genotyped) red cells would be necessary. It would be for negotiation between the RTC and Lorne who should undertake the genotyping of the cells. The question of recompensing the NBTS for any costs involved was not discussed in detail with the Company, but Lorne indicated that they were prepared to remunerate the RHA concerned in cash or in kind. It would not be difficult to draw up a suitable contract between the RHA and the Company (with Departmental guidance as appropriate) which would also cover the question of product liability.

6. A suggestion by Lorne that the Blood Group Reference Laboratory should assist in the quality control of their reagents is being pursued separately with the Scientific and Technical Committee of the Central Blood Laboratories.

7. The views of the Advisory Committee are sought on:

a. whether the materials described in paragraph 4 should be made available to Lorne Laboratories; and, if so,

b. whether a processing/handling charge should be imposed to recoup any costs involved.

June 1981 DHSS

44/271